Towa Pharmaceutical Co., Ltd. TSE:4553
Towa Pharmaceutical : FY2025 Supplementary Material of Financial Results(1.0M／46P)
Source: MarketScreener
2026
Notes to financial results disclosure material Notes
In this document, for the breakdown of the domestic segment,
Towa Pharmaceutical, J-Dolph Pharmaceutical, Daichi Kasei, Greencaps Pharmaceutical, and Kyushu Iyaku are referred to as "Towa Pharmaceutical, etc.," and Sunsho Pharmaceutical and Sun Freres Lab. are referred to as "Sunsho Pharmaceutical, etc."
On April 1, 2025, the Company carried out an absorption-type merger with Sunsho Pharmaceutical as the surviving company and KAMATA as the disappearing company.
Towa Pharma International Holdings, S.L., our overseas segment, is referred to as "Towa INT."
On May 11, we announced recognition of an impairment loss and a revision to our full-year earnings forecast for the fiscal year ended March 31, 2026.
"Towa Pharmaceutical, etc." "Sunsho Pharmaceutical, etc." "Towa INT"
Towa Pharmaceutical
J-Dolph
Pharmaceutical
Daichi Kasei
Greencaps
Pharmaceutical
Kyushu Iyaku
Sunsho
Pharmaceutical
Towa Pharma
International Holdings
Sun Freres Lab.
Towa Pharma
Europe
Breckenridge
Pharmaceutical
Towa
Pharmaceutical
2026 1
Table of contents
- Outline of financial results for 2026/3
- Full-year earnings plan for 2027/3
- Topics
- Reference materials
2026 2
Table of contents
- Outline of financial results for 2026/3
Full-year earnings plan for 2027/3
Topics
Reference materials
2026 3
Consolidated financial results for 2026/3- YoY change: Net sales increased, but operating profit decreased.
- Progress rate for the plan: Net sales: 97.8%, Operating profit: 85.6%.
-
Ordinary profit increased due to the posting of a 5.3 billion yen gain on valuation of derivatives.
(In 25/3, a 1.2 billion yen gain on valuation of derivatives was recognized.)
- Profit deceased due to the posting of an impairment loss of 14.7 billion yen on goodwill of Sunsho Pharmaceutical.
26/3 results | 25/3 results | 26/3 full-year plan (announced on May 15, 2025) | |||
(JPY billion) | YOY change (%) | (JPY billion) | (JPY billion) | Achievement rate (%) | |
Net sales | 273.7 | + 5.4% | 259.5 | 280.0 | 97.8% |
Gross profit | 99.1 | + 4.6% | 94.7 | 104.0 | 95.3% |
Operating profit | 23.1 | - 0.6% | 23.2 | 27.0 | 85.6% |
Ordinary profit | 28.0 | + 7.4% | 26.1 | 25.3 | 111.0% |
Profit attributable to owners of parent | 5.2 | - 72.3% | 18.9 | 17.7 | 29.7% |
Exchange rate at end of period(TTM) USD 1 | 26/3 | 25/3 | 24/3 |
JPY 159.88 | JPY 149.52 | JPY 151.41 |
2026 4